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Question:   
  
A 62-year-old female presented with haematological abnormalities of leukocytosis 
17.2x109/L (4 -11x109/L), specifically a persistent neutrophilia and monocytosis, with 
a bone marrow biopsy suggesting possible early chronic myeloid monocytic leukemia 
type I (hypercellular, 1% myeloblasts and 13% monocytes). Philadelphia chromosome 
and Bcr-abl were negative. The haemoglobin was 140-150g/L (R 115-155g/L) with a 
positive JAK2 mutation suggesting a diagnosis of Polycythemia Rubra Vera (PRV). She 
subsequently developed lethargy and non-specific bilateral costal margin 
discomfort. She was obese but no stigmata of chronic liver disease.  Her liver edge was 
palpable 4cm below the costal margin but no splenomegaly was detected. CT 
was performed (Fig A) showing at least 6 focal hepatic lesions, largest 62mm in 
segments 2 and 4 and splenomegaly of 16cm. Capsular retraction was seen in 
association with subcapsular lesions. The liver was not obviously cirrhotic. Her liver 
test showed Albumin 39 g/L, Bilirubin 10 µmol/L, ALP 110 U/L, GGT 61 U/L, AST 48 
U/L, ALT 27 U/L, LDH 604 U/L. Percutaneous targeted liver biopsies were 
indeterminate showing benign hepatocytes, fibrous bands and areas with 
proliferating ductules and inflammation.   
The largest lesion was biopsied at laparoscopy. The nodular lesion showed a 
circumscribed but non-encapsulated area of marked atrophy of the hepatic parenchyma 
with replacement by fibrosis (Fig B). Radiological follow-up over 15 months showed no 
progression.   
  
What is the diagnosis?   
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Answer :  
  
Histopathology revealed preserved portal tracts within the fibrosis, a prominent 
mononuclear inflammatory cell infiltrate and enlarged multinucleated bizarre 
cells. Islands of atrophic hepatocytes were present. Sinusoids and portal vein were 
focally lined by large atypical mononuclear and multinucleated cells (Fig B), with focal 
obliteration of portal vein branches by cells and fibrosis. Abnormal cells were Factor 
VIII positive and some of the atypical cells were myeloperoxidase positive; with 
some small nucleated cells, positive for glycophorin, an erythroid marker. There 
were extensive bone marrow cells including megakaryocytes and round cells in the non-
lesional liver interpreted as either haemopoietic or neoplastic chronic 
myeloid monocytic leukaemic cells suggestive of myeloid metaplasia. A final diagnosis 
of PRV associated Sclerosing Extramedullary Hematopoietic Tumour (SEMHT) of the 
liver was made.  
Extramedullary haematopoiesis (EMH) is a compensatory mechanism recognised in 
chronic myeloproliferative disorders including myelofibrosis, chronic myeloid 
leukemia and PRV. Most common sites are liver, spleen, and lymph nodes. Rarely, they 
are termed “sclerosing extramedullary haematopoietic tumour” (SEMHT) when 
fibroblastic proliferation accompanies a solid mass. The stroma of these tumours is 
usually loose connective tissue with variable degree of fibrosis, however when there is a 
predominant fibrosis, they have been referred as “fibrous haematopoietic tumours”. 
Remstein et al, used the term SEHMT to describe 
the extramedullary trilineage haematopoiesis and the predominant sclerotic 
background. Although rare, SEMHT have previously been described in spleen, 
on serosal surfaces and skin, lung, breast and orbit. [1,2,3]; and can histologically mimic 
other neoplasms including haemangioendothelioma. History of 
a haematological disorder and a high index of suspicion are important in making the 
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diagnosis. The clinical course of these tumours is relatively benign, and aggressive local 
therapy is not mandatory unless there is presence of mass effect symptoms.    
 
Fig. A 
 
 
 
Fig.B 
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